← All trials
NCT04392154
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Jul 31, 2022
- Completion date
- Nov 30, 2022
- First posted
- May 18, 2020
- Last posted
- May 18, 2020
- Enrollment
- 900
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dermira, Inc.Lead sponsor
- Eli LillyCollaborator
- Dermira, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.